Apellis Pharmaceuticals Inc
APLS24.970USD
-0.190-0.76%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
3.16BMarket Cap
70.44P/E TTM
More Details of Apellis Pharmaceuticals Inc Company
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.
Apellis Pharmaceuticals Inc Info
Ticker SymbolAPLS
Company nameApellis Pharmaceuticals Inc
IPO dateNov 09, 2017
CEOFrancois (Cedric)
Number of employees705
Security typeOrdinary Share
Fiscal year-endNov 09
Address100 Fifth Avenue
CityWALTHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02451
Phone16179775700
Websitehttps://apellis.com/
Ticker SymbolAPLS
IPO dateNov 09, 2017
CEOFrancois (Cedric)
Company Executives of Apellis Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Cedric Francois, M.D., Ph.D.
Dr. Cedric Francois, M.D., Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
1.61M
-4.95%
Dr. Pascal Deschatelets, Ph.D.
Dr. Pascal Deschatelets, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
1.12M
+1.15%
Mr. Alec Machiels, J.D.
Mr. Alec Machiels, J.D.
Independent Director
Independent Director
1.01M
-0.59%
Mr. David Osborne Watson, J.D.
Mr. David Osborne Watson, J.D.
General Counsel, Secretary
General Counsel, Secretary
92.58K
-5.12%
Ms. Nur Nicholson
Ms. Nur Nicholson
Chief Technical Operations Officer
Chief Technical Operations Officer
71.83K
+59.79%
Dr. Caroline Baumal, M.D.
Dr. Caroline Baumal, M.D.
Chief Medical Officer
Chief Medical Officer
41.19K
+557.11%
Mr. Craig A. Wheeler
Mr. Craig A. Wheeler
Independent Director
Independent Director
16.48K
--
Ms. Keli Walbert
Ms. Keli Walbert
Independent Director
Independent Director
9.09K
--
Ms. Stephanie Monaghan O'Brien, J.D.
Ms. Stephanie Monaghan O'Brien, J.D.
Independent Director
Independent Director
955.00
-86.25%
Mr. Niel Carnahan
Mr. Niel Carnahan
Investor Contact
Investor Contact
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Cedric Francois, M.D., Ph.D.
Dr. Cedric Francois, M.D., Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
1.61M
-4.95%
Dr. Pascal Deschatelets, Ph.D.
Dr. Pascal Deschatelets, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
1.12M
+1.15%
Mr. Alec Machiels, J.D.
Mr. Alec Machiels, J.D.
Independent Director
Independent Director
1.01M
-0.59%
Mr. David Osborne Watson, J.D.
Mr. David Osborne Watson, J.D.
General Counsel, Secretary
General Counsel, Secretary
92.58K
-5.12%
Ms. Nur Nicholson
Ms. Nur Nicholson
Chief Technical Operations Officer
Chief Technical Operations Officer
71.83K
+59.79%
Dr. Caroline Baumal, M.D.
Dr. Caroline Baumal, M.D.
Chief Medical Officer
Chief Medical Officer
41.19K
+557.11%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
By BusinessUSD
Name
Revenue
Proportion
SYFOVRE
150.63M
84.39%
EMPAVELI
20.76M
11.63%
Licensing and other revenue
7.11M
3.98%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
SYFOVRE
150.63M
84.39%
EMPAVELI
20.76M
11.63%
Licensing and other revenue
7.11M
3.98%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Wellington Management Company, LLP
10.87%
Morningside Venture Investments, Ltd.
10.12%
Avoro Capital Advisors LLC
9.66%
The Vanguard Group, Inc.
7.88%
Morgan Stanley & Co. LLC
7.26%
Other
54.21%
Shareholders
Shareholders
Proportion
Wellington Management Company, LLP
10.87%
Morningside Venture Investments, Ltd.
10.12%
Avoro Capital Advisors LLC
9.66%
The Vanguard Group, Inc.
7.88%
Morgan Stanley & Co. LLC
7.26%
Other
54.21%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
45.40%
Investment Advisor
23.60%
Hedge Fund
17.53%
Research Firm
10.49%
Corporation
10.12%
Individual Investor
3.78%
Bank and Trust
2.44%
Sovereign Wealth Fund
1.87%
Private Equity
1.84%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
652
131.04M
116.63%
+4.47M
2025Q3
672
126.71M
118.50%
-5.66M
2025Q2
699
132.30M
122.54%
+1.89M
2025Q1
718
128.54M
117.00%
-18.47M
2024Q4
706
128.71M
111.21%
+6.68M
2024Q3
691
120.87M
110.47%
+2.88M
2024Q2
680
117.66M
106.02%
+2.29M
2024Q1
677
115.10M
106.81%
-13.69M
2023Q4
648
115.71M
108.26%
-132.41K
2023Q3
622
115.96M
104.32%
-1.36M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Wellington Management Company, LLP
8.98M
7.11%
-3.33M
-27.04%
Jun 30, 2025
Morningside Venture Investments, Ltd.
12.81M
10.14%
--
--
Mar 31, 2025
Avoro Capital Advisors LLC
12.22M
9.68%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
10.14M
8.03%
+24.39K
+0.24%
Jun 30, 2025
Morgan Stanley & Co. LLC
7.57M
6%
-524.46K
-6.48%
Jun 30, 2025
Deep Track Capital LP
7.00M
5.54%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.48M
4.34%
+49.97K
+0.92%
Jun 30, 2025
AQR Capital Management, LLC
5.98M
4.73%
+1.90M
+46.57%
Jun 30, 2025
Jennison Associates LLC
2.66M
2.11%
+184.29K
+7.44%
Jun 30, 2025
State Street Investment Management (US)
3.56M
2.82%
-378.68K
-9.61%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Simplify Health Care ETF
1.92%
Virtus LifeSci Biotech Products ETF
1.78%
ALPS Medical Breakthroughs ETF
1.17%
State Street SPDR S&P Biotech ETF
0.88%
First Trust Health Care Alphadex Fund
0.83%
Direxion Daily S&P Biotech Bull 3X Shares
0.54%
ProShares Ultra Nasdaq Biotechnology
0.33%
First Trust Small Cap Growth AlphaDEX Fund
0.27%
Invesco Nasdaq Biotechnology ETF
0.26%
iShares Biotechnology ETF
0.2%
View more
Simplify Health Care ETF
Proportion1.92%
Virtus LifeSci Biotech Products ETF
Proportion1.78%
ALPS Medical Breakthroughs ETF
Proportion1.17%
State Street SPDR S&P Biotech ETF
Proportion0.88%
First Trust Health Care Alphadex Fund
Proportion0.83%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.54%
ProShares Ultra Nasdaq Biotechnology
Proportion0.33%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.27%
Invesco Nasdaq Biotechnology ETF
Proportion0.26%
iShares Biotechnology ETF
Proportion0.2%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Apellis Pharmaceuticals Inc?
The top five shareholders of Apellis Pharmaceuticals Inc are:
Wellington Management Company, LLP holds 8.98M shares, accounting for 7.11% of the total shares.
Morningside Venture Investments, Ltd. holds 12.81M shares, accounting for 10.14% of the total shares.
Avoro Capital Advisors LLC holds 12.22M shares, accounting for 9.68% of the total shares.
The Vanguard Group, Inc. holds 10.14M shares, accounting for 8.03% of the total shares.
Morgan Stanley & Co. LLC holds 7.57M shares, accounting for 6.00% of the total shares.
Wellington Management Company, LLP holds 8.98M shares, accounting for 7.11% of the total shares.
Morningside Venture Investments, Ltd. holds 12.81M shares, accounting for 10.14% of the total shares.
Avoro Capital Advisors LLC holds 12.22M shares, accounting for 9.68% of the total shares.
The Vanguard Group, Inc. holds 10.14M shares, accounting for 8.03% of the total shares.
Morgan Stanley & Co. LLC holds 7.57M shares, accounting for 6.00% of the total shares.
What are the top three shareholder types of Apellis Pharmaceuticals Inc?
The top three shareholder types of Apellis Pharmaceuticals Inc are:
Wellington Management Company, LLP
Morningside Venture Investments, Ltd.
Avoro Capital Advisors LLC
Wellington Management Company, LLP
Morningside Venture Investments, Ltd.
Avoro Capital Advisors LLC
How many institutions hold shares of Apellis Pharmaceuticals Inc (APLS)?
As of 2025Q4, 652 institutions hold shares of Apellis Pharmaceuticals Inc, with a combined market value of approximately 131.04M, accounting for 116.63% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.87%.
What is the biggest source of revenue for Apellis Pharmaceuticals Inc?
In FY2025Q2, the SYFOVRE business generated the highest revenue for Apellis Pharmaceuticals Inc, amounting to 150.63M and accounting for 84.39% of total revenue.
